Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
New findings from University of Oxford describe advances in life sciences
December 17th, 2008
"Vaccinia virus (VACV), the prototype poxvirus, encodes numerous proteins that modulate the host response to infection. Two such proteins, B14 and A52, act inside infected cells to inhibit activation of NF-kappa B, thereby blocking the production of pro-inflammatory cytokines," scientists in Oxford, the United Kingdom report. "We have solved the crystal structures of A52 and B14 at 1.9 angstrom and 2.7 angstrom resolution, respectively. Strikingly, both these proteins adopt a Bcl-2-like fold despite sharing no significant sequence similarity with other viral or cellular Bcl-2-like proteins. Unlike cellular and viral Bcl-2-like proteins described previously, A52 and B14...
Source: Vaccine Weekly (2008-12-17)
|
